Arteriovenous malformations (AVMs) are high-flow vascular malformations characterised by a complex vessel network directly connecting feeding arteries and draining veins, typically featured by a natural history of progression, while spontaneous regressions are purely anecdotal.AVMs are very aggressive entities that possess a locally infiltrative behaviour like neoplasms. Complete "radical" surgical excision presents the highest chance of cure, but nowadays there is still considerable controversy on how to treat large AVMs that are not amenable of "radical" excision.The aim of this paper is to propose a different approach to treat vast AVMs that cannot be removed radically.The association of an antiangiogenic drug (to be initiated before surgery and to be continued in the post-operative period), could prevent the feared "explosive" growth of the remaining nidus after its partial removal. This could make recontouring and other "aesthetically" focused procedures feasible in these patients, with an obvious leap in their quality of life.The most promising antiangiogenic drug seems to be Thalidomide, but other drugs such as Sirolimus, VEGF pathway inhibitors, Interferon or Matrix Metalloproteinase (MMP) Inhibitors could serve the purpose just as well. Even Propranolol could prove useful in this sense as suggested by some recent researches on retinopathy of prematurity and tumour biology.

Adjuvant role of anti-angiogenic drugs in the management of head and neck arteriovenous malformations / G. Colletti, P. Dalmonte, L. Moneghini, D. Ferrari, F. Allevi. - In: MEDICAL HYPOTHESES. - ISSN 0306-9877. - 85:3(2015), pp. 298-302. [10.1016/j.mehy.2015.05.016]

Adjuvant role of anti-angiogenic drugs in the management of head and neck arteriovenous malformations

G. Colletti
;
F. Allevi
Ultimo
2015

Abstract

Arteriovenous malformations (AVMs) are high-flow vascular malformations characterised by a complex vessel network directly connecting feeding arteries and draining veins, typically featured by a natural history of progression, while spontaneous regressions are purely anecdotal.AVMs are very aggressive entities that possess a locally infiltrative behaviour like neoplasms. Complete "radical" surgical excision presents the highest chance of cure, but nowadays there is still considerable controversy on how to treat large AVMs that are not amenable of "radical" excision.The aim of this paper is to propose a different approach to treat vast AVMs that cannot be removed radically.The association of an antiangiogenic drug (to be initiated before surgery and to be continued in the post-operative period), could prevent the feared "explosive" growth of the remaining nidus after its partial removal. This could make recontouring and other "aesthetically" focused procedures feasible in these patients, with an obvious leap in their quality of life.The most promising antiangiogenic drug seems to be Thalidomide, but other drugs such as Sirolimus, VEGF pathway inhibitors, Interferon or Matrix Metalloproteinase (MMP) Inhibitors could serve the purpose just as well. Even Propranolol could prove useful in this sense as suggested by some recent researches on retinopathy of prematurity and tumour biology.
Angiogenesis Inhibitors; Arteriovenous Malformations; Head; Humans; Neck; Medicine (all)
Settore MED/29 - Chirurgia Maxillofacciale
2015
Article (author)
File in questo prodotto:
File Dimensione Formato  
Adjuvant role of anti-angiogenic drugs in the management of head and neck arteriovenous malformations.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 272.74 kB
Formato Adobe PDF
272.74 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/467867
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 21
  • ???jsp.display-item.citation.isi??? 20
social impact